The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation

The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation

Abstract Background Tanimilast is a novel and selective inhaled inhibitor of phosphodiesterase-4 in advanced clinical development for chronic obstructive pulmonary disease (COPD). Tanimilast is known to exert prominent anti-inflammatory activity when tested in preclinical experimental models as well...

Full description

Bibliographic Details
Main Authors: Hoang Oanh Nguyen, Valentina Salvi, Laura Tiberio, Fabrizio Facchinetti, Mirco Govoni, Gino Villetti, Maurizio Civelli, Ilaria Barbazza, Carolina Gaudenzi, Mauro Passari, Tiziana Schioppa, Francesca Sozio, Annalisa Del Prete, Silvano Sozzani, Daniela Bosisio
Format: Article
Language:English
Published: BMC 2022-05-01
Series:Journal of Translational Medicine
Subjects:
CD141
Thrombomodulin
BDCA-3
cAMP
IL-13
Type 2 responses
Online Access:https://doi.org/10.1186/s12967-022-03402-x

Internet

https://doi.org/10.1186/s12967-022-03402-x

Similar Items